The GSK oncology products it has sold on to Novartis were worth approximately $2 billion in 2014, having posted a growth of around 32 per cent compared to the previous year. The drugs include ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources ... We sell different types of products and services to both investment professionals and individual ...

1). The insights they have provided through their partnership in pan-oncology and disease-specific patient councils are reflected in the design of clinical trials and in building GSK’s pipeline ...

In the segment, while products ... by 2031. GSK is increasing R&D investment in promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV ...